{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:56:51Z","timestamp":1791896211363,"version":"4.3.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T00:00:00Z","timestamp":1540425600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007388","name":"Compagnia di San Paolo","doi-asserted-by":"publisher","award":["2015.AAI4110.U4917"],"award-info":[{"award-number":["2015.AAI4110.U4917"]}],"id":[{"id":"10.13039\/100007388","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12967-018-1670-9","type":"journal-article","created":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T13:16:51Z","timestamp":1540473411000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["An increase in myocardial 18-fluorodeoxyglucose uptake is associated with left ventricular ejection fraction decline in Hodgkin lymphoma patients treated with anthracycline"],"prefix":"10.1186","volume":"16","author":[{"given":"Matteo","family":"Sarocchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bauckneht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Arboscello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selene","family":"Capitanio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Marini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Morbelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Miglino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela Giovanna","family":"Congiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Ghigliotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manrico","family":"Balbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Brunelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianmario","family":"Sambuceti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7167-7287","authenticated-orcid":false,"given":"Pietro","family":"Ameri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Spallarossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,25]]},"reference":[{"issue":"7","key":"1670_CR1","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1002\/ajh.23750","volume":"89","author":"SM Ansell","year":"2014","unstructured":"Ansell SM. Hodgkin lymphoma: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol. 2014;89(7):771\u20139.","journal-title":"Am J Hematol"},{"issue":"12","key":"1670_CR2","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1182\/blood-2015-11-679407","volume":"127","author":"SF Barrington","year":"2016","unstructured":"Barrington SF, Kirkwood AA, Franceschetto A, et al. PET-CT for staging and early response: results from the response-adapted therapy in advanced Hodgkin lymphoma study. Blood. 2016;127(12):1531\u20138. \n                    https:\/\/doi.org\/10.1182\/blood-2015-11-679407\n                    \n                  .","journal-title":"Blood"},{"issue":"1","key":"1670_CR3","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1186\/1471-2407-10-337","volume":"10","author":"LA Smith","year":"2010","unstructured":"Smith LA, Cornelius VR, Plummer CJ, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer. 2010;10(1):337. \n                    https:\/\/doi.org\/10.1186\/1471-2407-10-337\n                    \n                  .","journal-title":"BMC Cancer"},{"issue":"9","key":"1670_CR4","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/S1470-2045(16)30215-7","volume":"17","author":"N Bhakta","year":"2016","unstructured":"Bhakta N, Liu Q, Yeo F, et al. Cumulative burden of cardiovascular morbidity in paediatric, adolescent, and young adult survivors of Hodgkin\u2019s lymphoma: an analysis from the St Jude Lifetime Cohort Study. Lancet Oncol. 2016;17(9):1325\u201334.","journal-title":"Lancet Oncol"},{"issue":"6","key":"1670_CR5","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1001\/jamainternmed.2015.1180","volume":"175","author":"FA Nimwegen van","year":"2015","unstructured":"van Nimwegen FA, Schaapveld M, Janus CPM, et al. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med. 2015;175(6):1007\u201317. \n                    https:\/\/doi.org\/10.1001\/jamainternmed.2015.1180\n                    \n                  .","journal-title":"JAMA Intern Med"},{"issue":"18","key":"1670_CR6","doi-asserted-by":"publisher","first-page":"3431","DOI":"10.1200\/jco.2003.07.131","volume":"21","author":"BMP Aleman","year":"2003","unstructured":"Aleman BMP, van den Belt-Dusebout AW, Klokman WJ, van\u2019t Veer MB, Bartelink H, van Leeuwen FE. Long-term cause-specific mortality of patients treated for Hodgkin\u2019s disease. J Clin Oncol. 2003;21(18):3431\u20139. \n                    https:\/\/doi.org\/10.1200\/jco.2003.07.131\n                    \n                  .","journal-title":"J Clin Oncol"},{"issue":"10","key":"1670_CR7","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1200\/JCO.2004.06.033","volume":"22","author":"O Hequet","year":"2004","unstructured":"Hequet O, Le QH, Moullet I, et al. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol. 2004;22(10):1864\u201371. \n                    https:\/\/doi.org\/10.1200\/JCO.2004.06.033\n                    \n                  .","journal-title":"J Clin Oncol"},{"issue":"36","key":"1670_CR8","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","volume":"37","author":"JL Zamorano","year":"2016","unstructured":"Zamorano JL, Lancellotti P, Rodriguez Mu\u00f1oz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(36):2768\u2013801. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehw211\n                    \n                  .","journal-title":"Eur Heart J"},{"issue":"suppl 7","key":"1670_CR9","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1093\/annonc\/mds293","volume":"23","author":"G Curigliano","year":"2012","unstructured":"Curigliano G, Cardinale D, Suter T, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2012;23(suppl 7):155\u201366.","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"1670_CR10","doi-asserted-by":"publisher","first-page":"S84","DOI":"10.2459\/JCM.0000000000000381","volume":"17","author":"P Spallarossa","year":"2016","unstructured":"Spallarossa P, Maurea N, Cadeddu C, et al. A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology. J Cardiovasc Med Hagerstown Md. 2016;17(Suppl 1):S84\u201392. \n                    https:\/\/doi.org\/10.2459\/JCM.0000000000000381\n                    \n                  .","journal-title":"J Cardiovasc Med Hagerstown Md"},{"issue":"9","key":"1670_CR11","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.echo.2014.07.012","volume":"27","author":"JC Plana","year":"2014","unstructured":"Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;27(9):911\u201339. \n                    https:\/\/doi.org\/10.1016\/j.echo.2014.07.012\n                    \n                  .","journal-title":"J Am Soc Echocardiogr"},{"issue":"27","key":"1670_CR12","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1200\/jco.2013.53.5229","volume":"32","author":"SF Barrington","year":"2014","unstructured":"Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(27):3048\u201358. \n                    https:\/\/doi.org\/10.1200\/jco.2013.53.5229\n                    \n                  .","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"11","key":"1670_CR13","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1038\/nm.2919","volume":"18","author":"S Zhang","year":"2012","unstructured":"Zhang S, Liu X, Bawa-Khalfe T, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012;18(11):1639\u201342. \n                    https:\/\/doi.org\/10.1038\/nm.2919\n                    \n                  .","journal-title":"Nat Med"},{"key":"1670_CR14","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.117.030352","author":"M Li","year":"2018","unstructured":"Li M, Sala V, De Santis MC, et al. Phosphoinositide 3-kinase gamma inhibition protects from anthracycline cardiotoxicity and reduces tumor growth. Circulation. 2018. \n                    https:\/\/doi.org\/10.1161\/circulationaha.117.030352\n                    \n                  .","journal-title":"Circulation"},{"issue":"5","key":"1670_CR15","doi-asserted-by":"publisher","first-page":"220","DOI":"10.4329\/wjr.v4.i5.220","volume":"4","author":"C Borde","year":"2012","unstructured":"Borde C, Kand P, Basu S. Enhanced myocardial fluorodeoxyglucose uptake following adriamycin-based therapy: evidence of early chemotherapeutic cardiotoxicity? World J Radiol. 2012;4(5):220\u20133. \n                    https:\/\/doi.org\/10.4329\/wjr.v4.i5.220\n                    \n                  .","journal-title":"World J Radiol"},{"issue":"6","key":"1670_CR16","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1097\/RLU.0000000000001194","volume":"41","author":"AKR Gorla","year":"2016","unstructured":"Gorla AKR, Sood A, Prakash G, Parmar M, Mittal BR. Substantial increase in myocardial FDG uptake on interim PET\/CT may be an early sign of adriamycin-induced cardiotoxicity. Clin Nucl Med. 2016;41(6):462. \n                    https:\/\/doi.org\/10.1097\/RLU.0000000000001194\n                    \n                  .","journal-title":"Clin Nucl Med"},{"key":"1670_CR17","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.191122","author":"M Bauckneht","year":"2017","unstructured":"Bauckneht M, Ferrarazzo G, De Fiz F, et al. Doxorubicin effect on myocardial metabolism as a pre-requisite for subsequent development of cardiac toxicity: a translational 18F-FDG PET\/CT observation. J Nucl Med. 2017. \n                    https:\/\/doi.org\/10.2967\/jnumed.117.191122\n                    \n                  .","journal-title":"J Nucl Med"},{"key":"1670_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/jev113","author":"N Mousavi","year":"2015","unstructured":"Mousavi N, Tan TC, Ali M, Halpern EF, Wang L, Scherrer-Crosbie M. Echocardiographic parameters of left ventricular size and function as predictors of symptomatic heart failure in patients with a left ventricular ejection fraction of 50\u201359% treated with anthracyclines. Eur Heart J Cardiovasc Imaging. 2015. \n                    https:\/\/doi.org\/10.1093\/ehjci\/jev113\n                    \n                  .","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"supplement 1","key":"1670_CR19","first-page":"1549","volume":"55","author":"J Kim","year":"2014","unstructured":"Kim J, Park KS, Jeong G-C, et al. Routine oncologic FDG PET\/CT may be useful for evaluation of cancer therapy-induced cardiotoxicity. J Nucl Med. 2014;55(supplement 1):1549.","journal-title":"J Nucl Med"},{"issue":"22","key":"1670_CR20","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1161\/CIRCULATIONAHA.115.016704","volume":"131","author":"JD Groarke","year":"2015","unstructured":"Groarke JD, Nohria A. Anthracycline cardiotoxicity: a new paradigm for an old classic. Circulation. 2015;131(22):1946\u20139. \n                    https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.016704\n                    \n                  .","journal-title":"Circulation"},{"issue":"6","key":"1670_CR21","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.cardfail.2016.04.008","volume":"22","author":"V Mercurio","year":"2016","unstructured":"Mercurio V, Pirozzi F, Lazzarini E, et al. Models of heart failure based on the cardiotoxicity of anticancer drugs. J Card Fail. 2016;22(6):449\u201358. \n                    https:\/\/doi.org\/10.1016\/j.cardfail.2016.04.008\n                    \n                  .","journal-title":"J Card Fail"},{"issue":"18","key":"1670_CR22","doi-asserted-by":"publisher","first-page":"8839","DOI":"10.1158\/0008-5472.CAN-07-1649","volume":"67","author":"YL Lyu","year":"2007","unstructured":"Lyu YL, Kerrigan JE, Lin C-P, et al. Topoisomerase II mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res. 2007;67(18):8839\u201346. \n                    https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-1649\n                    \n                  .","journal-title":"Cancer Res"},{"key":"1670_CR23","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3389\/fphys.2018.00167","volume":"9","author":"G Varricchi","year":"2018","unstructured":"Varricchi G, Ameri P, Cadeddu C, et al. Antineoplastic drug-induced cardiotoxicity: a redox perspective. Front Physiol. 2018;9:167. \n                    https:\/\/doi.org\/10.3389\/fphys.2018.00167\n                    \n                  .","journal-title":"Front Physiol"},{"issue":"6","key":"1670_CR24","doi-asserted-by":"publisher","first-page":"H2169","DOI":"10.1152\/ajpheart.00068.2009","volume":"297","author":"P Spallarossa","year":"2009","unstructured":"Spallarossa P, Altieri P, Aloi C, et al. Doxorubicin induces senescence or apoptosis in rat neonatal cardiomyocytes by regulating the expression levels of the telomere binding factors 1 and 2. Am J Physiol Heart Circ Physiol. 2009;297(6):H2169\u201381. \n                    https:\/\/doi.org\/10.1152\/ajpheart.00068.2009\n                    \n                  .","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"2","key":"1670_CR25","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.tox.2010.01.019","volume":"270","author":"RA Carvalho","year":"2010","unstructured":"Carvalho RA, Sousa RPB, Cadete VJJ, et al. Metabolic remodeling associated with subchronic doxorubicin cardiomyopathy. Toxicology. 2010;270(2):92\u20138. \n                    https:\/\/doi.org\/10.1016\/j.tox.2010.01.019\n                    \n                  .","journal-title":"Toxicology"},{"issue":"3","key":"1670_CR26","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s12012-007-0026-0","volume":"7","author":"JM Berthiaume","year":"2007","unstructured":"Berthiaume JM, Wallace KB. Persistent alterations to the gene expression profile of the heart subsequent to chronic doxorubicin treatment. Cardiovasc Toxicol. 2007;7(3):178\u201391. \n                    https:\/\/doi.org\/10.1007\/s12012-007-0026-0\n                    \n                  .","journal-title":"Cardiovasc Toxicol"},{"issue":"5","key":"1670_CR27","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1111\/j.1471-4159.1977.tb10649.x","volume":"28","author":"L Sokoloff","year":"1977","unstructured":"Sokoloff L, Reivich M, Kennedy C, et al. The [14c]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat1. J Neurochem. 1977;28(5):897\u2013916. \n                    https:\/\/doi.org\/10.1111\/j.1471-4159.1977.tb10649.x\n                    \n                  .","journal-title":"J Neurochem"},{"issue":"4","key":"1670_CR28","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3390\/diagnostics7040057","volume":"7","author":"M Bauckneht","year":"2017","unstructured":"Bauckneht M, Morbelli S, Fiz F, et al. A score-based approach to 18F-FDG PET images as a tool to describe metabolic predictors of myocardial doxorubicin susceptibility. Diagnostics. 2017;7(4):57. \n                    https:\/\/doi.org\/10.3390\/diagnostics7040057\n                    \n                  .","journal-title":"Diagnostics"},{"issue":"1","key":"1670_CR29","doi-asserted-by":"publisher","first-page":"25092","DOI":"10.1038\/srep25092","volume":"6","author":"C Marini","year":"2016","unstructured":"Marini C, Ravera S, Buschiazzo A, et al. Discovery of a novel glucose metabolism in cancer: the role of endoplasmic reticulum beyond glycolysis and pentose phosphate shunt. Sci Rep. 2016;6(1):25092. \n                    https:\/\/doi.org\/10.1038\/srep25092\n                    \n                  .","journal-title":"Sci Rep"},{"key":"1670_CR30","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/S0005-2736(02)00612-0","volume":"1567","author":"S Hrelia","year":"2002","unstructured":"Hrelia S, Fiorentini D, Maraldi T, et al. Doxorubicin induces early lipid peroxidation associated with changes in glucose transport in cultured cardiomyocytes. Biochim Biophys Acta BBA Biomembr. 2002;1567:150\u20136. \n                    https:\/\/doi.org\/10.1016\/S0005-2736(02)00612-0\n                    \n                  .","journal-title":"Biochim Biophys Acta BBA Biomembr"},{"issue":"3","key":"1670_CR31","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jacc.2009.03.095","volume":"55","author":"D Cardinale","year":"2010","unstructured":"Cardinale D, Colombo A, Lamantia G, et al. Anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2010;55(3):213\u201320. \n                    https:\/\/doi.org\/10.1016\/j.jacc.2009.03.095\n                    \n                  .","journal-title":"J Am Coll Cardiol"},{"issue":"27","key":"1670_CR32","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059\u201367. \n                    https:\/\/doi.org\/10.1200\/JCO.2013.54.8800\n                    \n                  .","journal-title":"J Clin Oncol"},{"issue":"10","key":"1670_CR33","first-page":"1836","volume":"36","author":"JW Keyes","year":"1995","unstructured":"Keyes JW. SUV: standard uptake or silly useless value? J Nucl Med. 1995;36(10):1836\u20139.","journal-title":"J Nucl Med"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-018-1670-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12967-018-1670-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-018-1670-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T14:00:56Z","timestamp":1572012056000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-018-1670-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,25]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1670"],"URL":"https:\/\/doi.org\/10.1186\/s12967-018-1670-9","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,25]]},"assertion":[{"value":"20 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"295"}}